Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia

A. Michelutti, M. Michieli, D. Damiani, C. Melli, A. Geromin, D. Russo, R. Fanin, M. Baccarani

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background and methods. Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p 170) by immunocytochemistty (APAAP) with the MRK-16 monoclonal antibody. Results and conclusions. Positive cells were found in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89%). The proportion of positive cells, which ranged between less than 1% and 95%, was higher in blastic phase (mean 32 ± 29.9) than in chronic phase (mean 3 ± 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDB may contribute significantly to treatment failure.

Original languageEnglish
Pages (from-to)200-204
Number of pages5
JournalHaematologica
Volume79
Issue number3
Publication statusPublished - 1994

Fingerprint

Multiple Drug Resistance
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Glycoproteins
Treatment Failure
Monoclonal Antibodies
Drug Therapy

Keywords

  • chemotherapy
  • chronic myeloid leukemia
  • drug resistance

ASJC Scopus subject areas

  • Hematology

Cite this

Michelutti, A., Michieli, M., Damiani, D., Melli, C., Geromin, A., Russo, D., ... Baccarani, M. (1994). Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica, 79(3), 200-204.

Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. / Michelutti, A.; Michieli, M.; Damiani, D.; Melli, C.; Geromin, A.; Russo, D.; Fanin, R.; Baccarani, M.

In: Haematologica, Vol. 79, No. 3, 1994, p. 200-204.

Research output: Contribution to journalArticle

Michelutti, A, Michieli, M, Damiani, D, Melli, C, Geromin, A, Russo, D, Fanin, R & Baccarani, M 1994, 'Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia', Haematologica, vol. 79, no. 3, pp. 200-204.
Michelutti A, Michieli M, Damiani D, Melli C, Geromin A, Russo D et al. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica. 1994;79(3):200-204.
Michelutti, A. ; Michieli, M. ; Damiani, D. ; Melli, C. ; Geromin, A. ; Russo, D. ; Fanin, R. ; Baccarani, M. / Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. In: Haematologica. 1994 ; Vol. 79, No. 3. pp. 200-204.
@article{bc606dd7479b4f4d9f4d4c213e27372d,
title = "Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia",
abstract = "Background and methods. Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p 170) by immunocytochemistty (APAAP) with the MRK-16 monoclonal antibody. Results and conclusions. Positive cells were found in 11/17 cases in chronic phase (65{\%}), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89{\%}). The proportion of positive cells, which ranged between less than 1{\%} and 95{\%}, was higher in blastic phase (mean 32 ± 29.9) than in chronic phase (mean 3 ± 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDB may contribute significantly to treatment failure.",
keywords = "chemotherapy, chronic myeloid leukemia, drug resistance",
author = "A. Michelutti and M. Michieli and D. Damiani and C. Melli and A. Geromin and D. Russo and R. Fanin and M. Baccarani",
year = "1994",
language = "English",
volume = "79",
pages = "200--204",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia

AU - Michelutti, A.

AU - Michieli, M.

AU - Damiani, D.

AU - Melli, C.

AU - Geromin, A.

AU - Russo, D.

AU - Fanin, R.

AU - Baccarani, M.

PY - 1994

Y1 - 1994

N2 - Background and methods. Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p 170) by immunocytochemistty (APAAP) with the MRK-16 monoclonal antibody. Results and conclusions. Positive cells were found in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89%). The proportion of positive cells, which ranged between less than 1% and 95%, was higher in blastic phase (mean 32 ± 29.9) than in chronic phase (mean 3 ± 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDB may contribute significantly to treatment failure.

AB - Background and methods. Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p 170) by immunocytochemistty (APAAP) with the MRK-16 monoclonal antibody. Results and conclusions. Positive cells were found in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89%). The proportion of positive cells, which ranged between less than 1% and 95%, was higher in blastic phase (mean 32 ± 29.9) than in chronic phase (mean 3 ± 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDB may contribute significantly to treatment failure.

KW - chemotherapy

KW - chronic myeloid leukemia

KW - drug resistance

UR - http://www.scopus.com/inward/record.url?scp=0027935266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027935266&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 200

EP - 204

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -